XencorXNCR
XNCR
About: Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Employees: 250
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
55% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 53
19% more capital invested
Capital invested by funds: $1.45B [Q3] → $1.72B (+$274M) [Q4]
4.1% more ownership
Funds ownership: 102.98% [Q3] → 107.08% (+4.1%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
8% less funds holding
Funds holding: 209 [Q3] → 192 (-17) [Q4]
20% less call options, than puts
Call options by funds: $78K | Put options by funds: $97K
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$33
236%
upside
Avg. target
$33
236%
upside
High target
$33
236%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo 14% 1-year accuracy 1 / 7 met price target | 236%upside $33 | Overweight Maintained | 28 Feb 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Xencor Appoints Todd Simpson to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023.
Negative
Zacks Investment Research
1 month ago
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.
Neutral
Business Wire
1 month ago
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on XmAb® drug candidates that leverage our protein engineering strengths and reduce exposure to biologica.
Positive
Market Watch
1 month ago
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Neutral
Zacks Investment Research
1 month ago
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
2 months ago
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Negative
Zacks Investment Research
2 months ago
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
Zacks Investment Research
2 months ago
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
2 months ago
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Zacks Investment Research
3 months ago
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™